ClinicalTrials.Veeva

Menu
The trial is taking place at:
O

ONCOVIDA | Santiago, Chile

Veeva-enabled site

Efficacy and Safety of Pembrolizumab (MK-3475) Plus Lenvatinib (E7080/MK-7902) Plus Chemotherapy in Participants With Metastatic Esophageal Carcinoma (MK-7902-014/E7080-G000-320/LEAP-014)

Merck Sharp & Dohme (MSD) logo

Merck Sharp & Dohme (MSD)

Status and phase

Enrolling
Phase 3

Conditions

Metastatic Esophageal Squamous Cell Carcinoma

Treatments

Drug: Paclitaxel
Drug: Lenvatinib
Drug: Levoleucovorin
Drug: Leucovorin
Drug: Cisplatin
Drug: Oxaliplatin
Drug: Pembrolizumab
Drug: 5-FU

Study type

Interventional

Funder types

Industry

Identifiers

NCT04949256
LEAP-014 (Other Identifier)
2022-501342-29 (Registry Identifier)
U1111-1280-1020 (Other Identifier)
MK-7902-014 (Other Identifier)
7902-014
2020-001911-26 (EudraCT Number)
E7080-G000-320 (Other Identifier)

Details and patient eligibility

About

The purpose of this study is to assess the efficacy and safety of pembrolizumab plus lenvatinib plus chemotherapy compared with pembrolizumab plus chemotherapy as first-line intervention in participants with metastatic esophageal carcinoma

The primary hypotheses are that pembrolizumab plus lenvatinib plus chemotherapy is superior to pembrolizumab plus chemotherapy with respect to overall survival (OS) and progression-free survival (PFS) per Response Evaluation Criteria in Solid Tumors Version 1.1 (RECIST 1.1) by blinded independent central review (BICR).

Full description

There will be 2 parts to the study: the cisplatin and 5-fluorouracil (5-FU) (FP) and paclitaxel and cisplatin (TP) Safety Run-in (Part 1) and the Main Study (Part 2). In Part 1 (FP and TP Safety Run-in), participants will be treated with pembrolizumab plus lenvatinib plus FP or TP. Dose-limiting toxicities, safety, and tolerability will be assessed.

In Part 2 (Main Study), participants (not including those participating in Part 1) will be treated with pembrolizumab plus lenvatinib plus chemotherapy or pembrolizumab plus chemotherapy. Efficacy, safety, and tolerability will be assessed.

Enrollment

862 estimated patients

Sex

All

Ages

18+ years old

Volunteers

No Healthy Volunteers

Inclusion criteria

  • Has a histologically or cytologically confirmed diagnosis of metastatic squamous cell carcinoma of the esophagus
  • Male participants are abstinent from heterosexual intercourse or agree to use contraception during the intervention period and for at least 7 days after the last dose of lenvatinib or 90 days after the last dose of chemotherapy, whichever comes last; 7 days after lenvatinib is stopped, if the participant is on pembrolizumab only and is greater than 90 days post chemotherapy, no male contraception is needed
  • Female participant is not pregnant or breastfeeding and is not a woman of childbearing potential (WOCBP) or is a WOCBP using a contraceptive method that is highly effective or is abstinent from heterosexual intercourse as their preferred and usual lifestyle during the intervention period and for at least 120 days after the last dose of pembrolizumab, 30 days after the last dose of lenvatinib, or 180 days after the last dose of chemotherapy, whichever occurs last, and agrees not to donate eggs during this period
  • Has adequately controlled blood pressure (BP) with or without antihypertensive medications, defined as BP≤150/90 millimeters of mercury (mm Hg) with no change in antihypertensive medications within 1 week prior to randomization
  • Has adequate organ function

Exclusion criteria

  • Has had previous therapy for locally advanced unresectable or metastatic esophageal cancer
  • Has locally advanced esophageal carcinoma
  • Has metastatic adenocarcinoma of the esophagus
  • Has direct invasion into adjacent organs such as the aorta or trachea
  • Has radiographic evidence of encasement of a major blood vessel, or of intratumoral cavitation
  • Has perforation risks or significant gastrointestinal (GI) bleeding
  • Has had clinically significant hemoptysis within 3 weeks prior to the first dose of study drug or tumor bleeding within 2 weeks prior to the first dose of study intervention
  • Has uncontrollable pleural effusion, pericardial effusion, or ascites requiring frequent drainage or medical intervention
  • Has GI obstruction, poor oral intake, difficulty in taking oral medication, or existing esophageal stent
  • Has had major surgery, open biopsy, or significant traumatic injury within 3 weeks prior to first dose of study interventions
  • Has received prior radiotherapy within 2 weeks of start of study intervention or have had a history of radiation pneumonitis
  • Has received a live or live attenuated vaccine within 30 days prior to the first dose of study intervention; administration of killed vaccines is allowed
  • Has a diagnosis of immunodeficiency or is receiving chronic systemic steroid therapy or any form of immunosuppressive therapy within 7 days prior to the first dose of study intervention, or has a history of organ transplant, including allogeneic stem cell transplant
  • Has a known additional malignancy that is progressing or has required active treatment within the past 3 years
  • Has known active central nervous system (CNS) metastases and/or carcinomatous meningitis
  • Has an active autoimmune disease that has required systemic treatment in past 2 years; replacement therapy is not considered a form of systemic treatment and is allowed
  • Has a history of non-infectious pneumonitis/interstitial lung disease that required steroids or current pneumonitis/interstitial lung disease
  • Has poorly controlled diarrhea
  • Has clinically significant cardiovascular disease within 12 months from first dose of study intervention
  • Has peripheral neuropathy ≥Grade 2
  • Has a known history of human immunodeficiency virus (HIV) infection
  • Has a known history of Hepatitis B or know active Hepatitis C virus infection
  • Has a weight loss of >20% within the last 3 months

Trial design

Primary purpose

Treatment

Allocation

Randomized

Interventional model

Parallel Assignment

Masking

None (Open label)

862 participants in 2 patient groups

Pembrolizumab + Lenvatinib + Chemotherapy
Experimental group
Description:
Participants receive pembrolizumab intravenously (IV) plus lenvatinib orally in combination with FP or TP in Part 1, or in combination with investigator's choice of chemotherapy with FP IV or TP IV or oxaliplatin, 5-FU and leucovorin (mFOLFOX6) IV in Part 2. Induction consists of pembrolizumab 400 mg once every 6-weeks (Q6W) for up to \~12 weeks plus lenvatinib 8 mg once daily (QD) for up to \~12 weeks plus chemotherapy with FP (cisplatin 80 mg/m\^2 and 5-FU 4000 mg/m\^2) or TP (paclitaxel 175 mg/m\^2 and cisplatin 75 mg/m\^2) once every 3 weeks (Q3W) for up to \~12 weeks or mFOLFOX6 (oxaliplatin 85 mg/m\^2, 5-FU 400 mg/m\^2 followed by 2400 mg/m\^2, and leucovorin 400 mg/m\^2 \[or levoleucovorin 200 mg/m\^2\] once every 2 weeks \[Q2W\] for up to \~12 weeks). This is followed by consolidation with pembrolizumab 400 mg Q6W for up to 16 cycles (each cycle = 6 weeks; total pembrolizumab treatment duration is \~2 years) plus lenvatinib 20 mg QD until progressive disease or discontinuation.
Treatment:
Drug: 5-FU
Drug: Oxaliplatin
Drug: Cisplatin
Drug: Pembrolizumab
Drug: Leucovorin
Drug: Levoleucovorin
Drug: Lenvatinib
Drug: Paclitaxel
Pembrolizumab + Chemotherapy
Active Comparator group
Description:
Participants receive pembrolizumab 400 mg IV Q6W for up to 18 cycles (each cycle = 6 weeks; total pembrolizumab treatment duration is \~2 years) in combination with investigator's choice of chemotherapy with FP (cisplatin 80 mg/m\^2 IV Q3W for up to 6 administrations \[up to \~18 weeks\] and 5-FU 4000 mg/m\^2 IV Q3W for up to 35 administrations \[up to \~2 years\]) or TP (paclitaxel 175 mg/m\^2 and cisplatin 75 mg/m\^2 Q3W for up 6 administrations \[up to \~18 weeks\]) or in combination with mFOLFOX6 (oxaliplatin 85 mg/m\^2, 5-FU 400 mg/m\^2 followed by 2400 mg/m\^2 and leucovorin 400 mg/m\^2 \[or levoleucovorin 200 mg/m\^2\] IV Q2W for up to 52 administrations \[approximately 2 years\]), during Part 2.
Treatment:
Drug: 5-FU
Drug: Oxaliplatin
Drug: Cisplatin
Drug: Pembrolizumab
Drug: Leucovorin
Drug: Levoleucovorin
Drug: Paclitaxel

Trial contacts and locations

195

Loading...

Central trial contact

Toll Free Number

Data sourced from clinicaltrials.gov

Clinical trials

Find clinical trialsTrials by location
© Copyright 2024 Veeva Systems